Biomarker Assessment of HR Deficiency, Tumor BRCA1/2 Mutations, and CCNE1 Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy

The current study evaluated three biomarkers [homologous recombination deficiency (HRD), tumor BRCA1/2 (tBRCA) mutations, and CCNE1 copy-number variation (CNV)] in ovarian tumors from patients enrolled on the SCOTROC4 clinical trial for associations with outcome following carboplatin monotherapy. Ov...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular cancer research 2018-07, Vol.16 (7), p.1103-1111
Hauptverfasser:	Stronach, Euan A, Paul, James, Timms, Kirsten M, Hughes, Elisha, Brown, Krystal, Neff, Christopher, Perry, Michael, Gutin, Alexander, El-Bahrawy, Mona, Steel, Jennifer H, Liu, Xinxue, Lewsley, Liz-Anne, Siddiqui, Nadeem, Gabra, Hani, Lanchbury, Jerry S, Brown, Robert
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Amplification Biomarkers Biomarkers, Tumor - genetics BRCA1 protein BRCA1 Protein - genetics BRCA2 Protein - genetics Breast cancer Cancer Carboplatin Carboplatin - administration & dosage Copy number Cyclin E - genetics Disease-Free Survival DNA Copy Number Variations - genetics Female Homologous recombination Homologous Recombination - genetics Homology Humans Loss of Heterozygosity Middle Aged Mutation Oncogene Proteins - genetics Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - genetics Ovarian Neoplasms - pathology Patients Platinum Subgroups Survival Treatment Outcome Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!